236 related articles for article (PubMed ID: 16505485)
1. Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein.
Maki N; Moitra K; Ghosh P; Dey S
J Biol Chem; 2006 Apr; 281(16):10769-77. PubMed ID: 16505485
[TBL] [Abstract][Full Text] [Related]
2. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
[TBL] [Abstract][Full Text] [Related]
3. Functionally similar vanadate-induced 8-azidoadenosine 5'-[alpha-(32)P]Diphosphate-trapped transition state intermediates of human P-glycoprotin are generated in the absence and presence of ATP hydrolysis.
Sauna ZE; Smith MM; Muller M; Ambudkar SV
J Biol Chem; 2001 Jun; 276(24):21199-208. PubMed ID: 11287418
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes.
Sauna ZE; Ambudkar SV
J Biol Chem; 2001 Apr; 276(15):11653-61. PubMed ID: 11154703
[TBL] [Abstract][Full Text] [Related]
5. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.
Dey S; Ramachandra M; Pastan I; Gottesman MM; Ambudkar SV
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10594-9. PubMed ID: 9380680
[TBL] [Abstract][Full Text] [Related]
6. Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates.
Ghosh P; Moitra K; Maki N; Dey S
Arch Biochem Biophys; 2006 Jun; 450(1):100-12. PubMed ID: 16624245
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1).
Maki N; Dey S
Biochem Pharmacol; 2006 Jul; 72(2):145-55. PubMed ID: 16729976
[TBL] [Abstract][Full Text] [Related]
8. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation.
Maki N; Hafkemeyer P; Dey S
J Biol Chem; 2003 May; 278(20):18132-9. PubMed ID: 12642584
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein.
Sauna ZE; Ambudkar SV
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2515-20. PubMed ID: 10716986
[TBL] [Abstract][Full Text] [Related]
10. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.
Dey S; Hafkemeyer P; Pastan I; Gottesman MM
Biochemistry; 1999 May; 38(20):6630-9. PubMed ID: 10350482
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the vectorial nature of drug (substrate)-stimulated ATP hydrolysis by human P-glycoprotein.
Sauna ZE; Smith MM; Müller M; Ambudkar SV
J Biol Chem; 2001 Sep; 276(36):33301-4. PubMed ID: 11451943
[TBL] [Abstract][Full Text] [Related]
12. Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates.
Kerr KM; Sauna ZE; Ambudkar SV
J Biol Chem; 2001 Mar; 276(12):8657-64. PubMed ID: 11121420
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site.
Urbatsch IL; Sankaran B; Weber J; Senior AE
J Biol Chem; 1995 Aug; 270(33):19383-90. PubMed ID: 7642618
[TBL] [Abstract][Full Text] [Related]
14. Both ATP sites of human P-glycoprotein are essential but not symmetric.
Hrycyna CA; Ramachandra M; Germann UA; Cheng PW; Pastan I; Gottesman MM
Biochemistry; 1999 Oct; 38(42):13887-99. PubMed ID: 10529234
[TBL] [Abstract][Full Text] [Related]
15. Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity.
Julien M; Gros P
Biochemistry; 2000 Apr; 39(15):4559-68. PubMed ID: 10758006
[TBL] [Abstract][Full Text] [Related]
16. Both P-glycoprotein nucleotide-binding sites are catalytically active.
Urbatsch IL; Sankaran B; Bhagat S; Senior AE
J Biol Chem; 1995 Nov; 270(45):26956-61. PubMed ID: 7592942
[TBL] [Abstract][Full Text] [Related]
17. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle.
Qu Q; Russell PL; Sharom FJ
Biochemistry; 2003 Feb; 42(4):1170-7. PubMed ID: 12549939
[TBL] [Abstract][Full Text] [Related]
18. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.
Shepard RL; Winter MA; Hsaio SC; Pearce HL; Beck WT; Dantzig AH
Biochem Pharmacol; 1998 Sep; 56(6):719-27. PubMed ID: 9751076
[TBL] [Abstract][Full Text] [Related]
19. Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1).
Sauna ZE; Müller M; Peng XH; Ambudkar SV
Biochemistry; 2002 Nov; 41(47):13989-4000. PubMed ID: 12437356
[TBL] [Abstract][Full Text] [Related]
20. Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein.
Mandal D; Moitra K; Ghosh D; Xia D; Dey S
Biochemistry; 2012 Apr; 51(13):2852-66. PubMed ID: 22360349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
